U.S. Markets close in 5 hrs 57 mins

Merck stock up slightly after FDA approves Recarbrio for new indication

Sarah Toy

Shares of Merck & Co Inc. ticked up 0.5% in premarket trade Wednesday after the company said the U.S. Food and Drug Administration had approved its antibacterial Recarbrio injection for use in treating complicated urinary tract infections. The drug is also approved for use in adult patients who have limited options for the treatment of complicated intra-abdominal infections caused by certain bacteria. Merck said it expects to make the drug available later this year. Shares of Merck have gained 6.8% so far this year through Wednesday, while the S&P 500 has gained 19.8%.